In the BioHarmony Drug Report Database
Lumasiran
Oxlumo (lumasiran) is an oligonucleotide pharmaceutical. Lumasiran was first approved as Oxlumo on 2020-11-19. It has been approved in Europe to treat primary hyperoxaluria. Oxlumo’s patents are valid until 2035-10-09 (FDA).
Trade Name
|
Oxlumo |
|---|---|
Common Name
|
lumasiran |
ChEMBL ID
|
CHEMBL4297779 |
Indication
|
primary hyperoxaluria |
Drug Class
|
Image (chem structure or protein)
